Search Results
Jun 01, 2026, 06:30 ET Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
history analyses of symptomatic patientsSKY-0515 patients achieved reductions of 69% mutant huntingtin protein (mHTT) at the 9 mg dose at twelve monthsThe Company also announces that the Australia and New Zealand (004-ANZ) portion of its Phase 2/3 FALCON-HD
More news about: Skyhawk Therapeutics
Jun 01, 2026, 04:19 ET Sobi to present new data on pegcetacoplan at ERA 2026
the only study to include adolescent and adult patients, with native and post-transplant kidneys. Study participants were randomised to receive 1080 mg of pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomised controlled period, patients were able to proceed to a 26-week
More news about: Swedish Orphan Biotrauma AB
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
52.6%-84.3%).Among 40 patients treated at the 2.0 mg/kg Q2W dose, median rPFS was also not reached (95% CI, 13.1-NE), with a 12-month rPFS rate of 78.6% (95% CI, 50.
More news about: Minghui Pharmaceutical
May 31, 2026, 20:15 ET ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
monotherapy), n=57: CS2009 was dosed at 10–45 mg/kg, once every 3 weeks (Q3W);(2) Group 2 (2/3L NSCLC combination therapy), n=9: CS2009 was dosed at 20 or 30 mg/kg, Q3W plus docetaxel;(3) Group 3 (1L NSCLC monotherapy ), n=23: CS2009 was dosed at 20 or 30 mg/kg, Q3W;(4) Group 4 (1L squamous
More news about: CStone Pharmaceuticals
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
end of this article.3→1.5 mg/kg IBI363 dose group:3 mg/kg + PDC in cycle 1, followed by 1.5 mg/kg once every 3 weeks (Q3W) + PDC1.5 mg/kg IBI363 dose group: 1.5 mg/kg Q3W + PDC3 mg/kg IBI363 dose group: 3 mg/kg Q3W + PDCAmong the 80 patients, the
More news about: Innovent Biologics
May 31, 2026, 20:00 ET 2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
Among the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months, and the median OS achieved 15.2
More news about: Innovent Biologics
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
previously untreated G12Cmut NSCLC received elisrasib 600 mg once daily in combination with pembrolizumab 200 mg every 3 weeks (Q3W), with a median study follow-up of 5.7 months. Notably, the dose of elisrasib used in combination is elisrasib's RP2D at 600mg QD which provides complete KRAS G12C target coverage.The
More news about: D3 Bio
May 31, 2026, 20:00 ET 德昇濟醫藥在ASCO 2026公布Elisrasib（D3S-001）一線治療數據；新一代KRAS G12C抑制劑在初治NSCLC中展現裡程碑式療效
G12C突變NSCLC在聯合治療隊列中，共有52例既往未接受治療的G12C突變NSCLC患者接受elisrasib 600 mg每日一次聯合帕博利珠單抗200 mg每3周一次（Q3W）治療，中位隨訪時間為5.7個月。值得注意的是，聯合方案中elisrasib的給藥劑量即為其RP2D（600 mg QD），可實現對KRAS G12C靶點的完全覆蓋。elisrasib聯合帕博利珠單抗在既往未接受治療的G12C突變NSCLC患者中展現出極具說服力的抗腫瘤活性。在48例療效可評估患者中，ORR為81.3%，且在各PD-L1表達水平人群中均觀察到療效：PD-L1 TPS <1%人群ORR為70.6%（n=17），TPS
More news about: 德昇濟醫藥（D3 Bio）
May 31, 2026, 17:36 ET Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
mutation who have undergone surgery as their only treatment.As of March 7, 2023, 331 patients were randomized globally to receive VORANIGO 40 mg daily (n=168) or placebo (n=163) continuously in 28-day cycles. Of the 331 patients, 172 had oligodendroglioma (88 VORANIGO; 84 placebo) and 159 patients
More news about: Servier Pharmaceuticals
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
metastatic disease, as determined by conventional imaging, were excluded from the study.10 Apalutamide was administered orally at 240 mg once daily. All study participants underwent protocol-defined surgery and were followed for long-term outcomes, including recurrence and progression.
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Retevmo-related adverse reactions in patients with hepatic impairment.Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.SE HCP ISI LA_NOV2025Please see full
More news about: Eli Lilly and Company
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
longer treatment.Tumor response is durable, with 6 months progression free survival (PFS) rates at 70.6% and 61.8%, respectively for 40 mg and 60 mg cohorts. The median duration of response (DoR) was not reached.Excellent blood-brain barrier (BBB) penetration was observed, including
More news about: Dizal Pharmaceutical
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
(258-345 mg) più capivasertib (320-400 mg) (n=31), che dimostrano un beneficio preliminare in termini di sopravvivenza mediana libera da progressione (mPFS) nella coorte trattata con la dose raccomandata per la fase 2 (RP2D). La RP2D è stata determinata nella coorte 2 (n=9) come elacestrant 345 mg più capivasertib
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
elacestranto (258-345 mg) mais capivasertibe (320-400 mg) (n=31), que demonstram um benefício preliminar na sobrevida média livre de progressão (mPFS) na coorte da dose recomendada para a fase 2 (RP2D). A RP2D foi determinada na coorte 2 (n=9) como sendo 345 mg de elacestranto mais 320 mg de capivasertibe
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
elacestrant (258-345 mg) más capivasertib (320-400 mg) (n=31), que demuestran la mediana preliminar del beneficio de supervivencia libre de progresión (mPFS) en la cohorte de dosis recomendada de fase 2 (RP2D). Se determinó que la RP2D en la cohorte 2 (n=9) era 345 mg de elacestrant más 320 mg de capivasertib
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 06:52 ET Menarini Group、ASCO2026でER+/HER2-転移性乳がん対象エラセストラント・カピバセルチブ併用ELEVATE試験の新データを発表
の治療レジメンで構成されています。ASCO2026で報告されるELEVATE試験の結果（抄録番号1098）[1]には、第1b相エラセストラント（258～345mg）＋カピバセルチブ（320～400mg）コホート（n=31）の安全性および予備的有効性データが含まれ、推奨第2相用量（RP2D）コホートにおける無増悪生存期間中央値（mPFS）の予備的ベネフィットが示されています。RP2Dはコホート2（n=9）で、エラセストラント345mg＋カピバセルチブ320mgを1日2回（4日間投与/3日間休薬）と決定されました。RP2Dの奏効評価可能な患者では、
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
Elacestrant (258–345 mg) plus Capivasertib (320–400 mg) (n = 31), die einen vorläufigen Vorteil hinsichtlich des medianen progressionsfreien Überlebens (mPFS) in der Kohorte mit der empfohlenen Phase-2-Dosis (RP2D) belegen. In Kohorte 2 (n = 9) wurde die empfohlene Tagesdosis (RP2D) auf 345 mg Elacestrant plus
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
(résumé 1098)[1] comprennent les données d'innocuité et d'efficacité préliminaire des cohortes de phase 1b élacestrant (258-345 mg) plus capivasertib (320-400 mg) (n=31), qui démontrent un bénéfice préliminaire sur le plan de la survie médiane sans progression (mPFS) dans la cohorte à la dose recommandée
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:53 ET Fox ESS anuncia su cambio de marca antes de la feria SNEC, presentando una nueva trayectoria de marca
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:50 ET Fox ESS kondigt zijn rebranding aan in aanloop naar de SNEC-beurs en luidt daarmee een nieuw hoofdstuk voor het merk in.
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:46 ET Fox ESS annonce son repositionnement de marque avant l'exposition SNEC, dévoilant un nouveau parcours de marque
Vidéo - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4 Logo - https://mma.prnewswire.com/media/2989536/5991642/Fox_ESS_logo.jpg
More news about: Fox ESS
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
있다.ASCO 2026에서 보고되는 ELEVATE 결과(초록 1098)[1]에는 제1b상 엘라세스트란트(258~345mg)와 카피바서팁(320~400mg) 병용 코호트(n=31)의 안전성 및 예비 유효성 데이터가 포함되며, 권장 2상 용량(RP2D) 코호트에서 예비 중위 무진행 생존기간(mPFS) 이익을 입증했다. RP2D는 코호트 2(n=9)에서 엘라세스트란트 345mg과 카피바서팁 320mg 1일 2회(BID)(4일 투여/3일 휴약)로 결정됐다.RP2D 반응 평가 가능 환자에서 예비 유효성은 질병 조절률(DCR)
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:00 ET Myasthenia Gravis Foundation of America (MGFA) Announces the Start of Myasthenia Gravis Awareness Month Around the World
years to diagnose MG, which is too long to live with life-changing symptoms. Raising awareness about MG can potentially help those impacted find treatments quicker - taking action for broader MG awareness can make a difference.In light of the damaging impact of the disease, MG community members
More news about: Myasthenia Gravis Foundation of America, Inc.
May 29, 2026, 09:33 ET Novo Nordisk amplia acesso à semaglutida biológica com preços até 50% mais baixos para tratamento de obesidade e diabetes no Brasil
para Wegovy® na dosagem 2,4 mg permite a aquisição de 3 (três) canetas pelo preço de 2 (duas). As condições especiais para Wegovy® 2,4mg são válidas até o final do mês de junho.Já para Rybelsus®, seguem as condições diferenciadas em todas as dosagens de 3 mg, 7 mg e 14 mg, por tempo indeterminado.
More news about: Novo Nordisk
May 29, 2026, 09:20 ET Neues Branding, neue Ära: Fox ESS positioniert sich vor der SNEC neu
Video - https://mma.prnewswire.com/media/2989568/final_MG_video.mp4Logo - https://mma.prnewswire.com/media/2989536/Fox_ESS_logo.jpg
More news about: Fox ESS